Genovis Q2 2025: Undramatic report but recent developments are case supporting - Redeye

Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimates and the recently expanded licese agreement with Thermo Fischer which we find supportive to the long-term case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1121872/genovis-q2-2025-undramatic-report-but-recent-developments-are-case-supporting?utm_source=finwire&utm_medium=RSS